Advertisement

Search Results

Advertisement



Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6182 pages

Showing 3651 - 3700


Frederick W. Alt, PhD, Honored With 2021 AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) is recognizing geneticist Frederick W. Alt, PhD, with the 18th AACR Award for Lifetime Achievement in Cancer Research. Dr. Alt is a Howard Hughes Medical Institute investigator, Director of the Program in Cellular and Molecular Medicine at Boston ...

Maryam Lustberg, MD, MPH, Accepts Leadership Roles at Smilow Cancer Hospital, Yale Cancer Center

Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from...

Chênevert Family Brain Tumor Center Launched at Yale

Yale School of Medicine recently announced a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Center will be a leading institution in worldwide neuro-oncology research, bringing groundbreaking solutions and hope to patients with brain tumors. The gift will...

breast cancer
issues in oncology

John Marshall, MD, and Liza Marshall: When Cancer Strikes an Oncologist’s Family

John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a breast cancer survivor, talk about the impact of her diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their memoir has an important message.

kidney cancer
issues in oncology

Study Explores Racial Disparities in Renal Cell Carcinoma by Stage and Mortality

Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...

covid-19

Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden

Loneliness and social isolation have been significant problems for the general population during the COVID-19 pandemic, but for patients with cancer, these issues were particularly acute, likely due to isolation and social distancing, according to a recent study published by Miaskowski et al in the ...

prostate cancer
issues in oncology

Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race

A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...

solid tumors
issues in oncology

AI System May Aid in Diagnosing Cancer of Unknown Primary

In 1% to 2% of cancer cases, the primary site of tumor origin cannot be determined. Because many modern cancer therapeutics target primary tumors, the prognosis for a cancer of unknown primary (CUP) is poor, with a median overall survival of 2.7 to 16 months. In order to receive a more specific...

Karen E. Knudsen, MBA, PhD: The American Cancer Society’s First Female CEO Speaks Out

Karen E. Knudsen, MBA, PhD, of Sidney Kimmel Cancer Center at Jefferson Health, was recently appointed Chief Executive Officer of the American Cancer Society—the first female to head the organization in its 107-year history. Dr. Knudsen talks about the opportunities she sees ahead for the Society...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer

On May 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...

lung cancer
issues in oncology

Accuracy of Lung Cancer Risk Model in Diverse Populations

A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...

issues in oncology
palliative care

Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer

There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel to help fill this void. In a study published by Emily Johnston, MD, MS, and colleagues in the journal...

issues in oncology

Imaging Study Aims to Detect Rates of Cancer in Medieval Britain

The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...

colorectal cancer

Risk of Colorectal Cancer and Colorectal Polyps in First-Degree Family Members

Researchers have demonstrated a possible connection between colorectal polyps in close relatives and the risk of developing colorectal cancer. The study, which was published by Song et al in the British Medical Journal, is of potential consequence for cancer screening procedures. Colorectal cancer...

bladder cancer
lung cancer
immunotherapy

FDA Pipeline: Priority Reviews of Treatments for Bladder and Lung Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review designation to treatments for surgically resected, high-risk, muscle-invasive urothelial carcinoma and epidermal growth factor receptor exon 20 insertion mutation–positive metastatic non–small cell lung cancer (NSCLC)....

hematologic malignancies
immunotherapy
symptom management

Antiviral T Cells for BK Virus–Associated Hemorrhagic Cystitis

A phase II trial has found found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis, a painful complication that is common after allogeneic stem cell transplants for patients with leukemia or lymphoma. ...

gastrointestinal cancer
gastroesophageal cancer
hepatobiliary cancer
immunotherapy

More From the FDA ODAC: Votes on Agents for Pretreated Hepatocellular Carcinoma and Gastric Cancer

More news has emerged from this week’s meeting of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). The group voted 8 to 0 in favor of continuing the accelerated approval for pembrolizumab in sorafenib-pretreated patients with hepatocellular carcinoma; 6 to 2...

breast cancer
issues in oncology

Fertility Concerns May Influence Decisions About Endocrine Therapy in Young Women With Breast Cancer

Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy, according to findings from a recent study published by Sella et al in the journal Cancer. The findings reinforce the need for...

bladder cancer
immunotherapy

FDA ODAC Votes in Favor of Retaining Accelerated Approval for Bladder Cancer Treatments

Roche has announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining the accelerated approval of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for...

breast cancer
legislation
health-care policy

Breast Reconstruction Disparities Improved With Medicaid Expansion

Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction among non-Hispanic Black women, achieving parity at times with non-Hispanic White women, according to a new study presented by Sharon Lum, MD, and colleagues at the American Society...

breast cancer
survivorship

Low-Risk Breast Cancer Survivors May Experience Long-Term Physical and Psychological Effects

Survivors of low-risk breast cancer may experience wide-ranging and significant physical and psychological symptoms after cancer treatment, according to a new study presented by Jessica Schumacher, PhD, and colleagues at the American Society of Breast Surgeons (ASBrS) Annual Meeting. Researchers...

breast cancer

Cryoablation Emerging as Effective Treatment for Low-Risk Breast Cancers

Nonsurgical breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, is proving to be an effective alternative to surgery for small breast tumors with low-risk features in women older than age 60. These were the early findings from 3-year results of the...

breast cancer
covid-19

COVID-19 Pandemic Drove Strategic New Breast Cancer Approaches to Avoid Hospitalization

The COVID-19 pandemic rapidly altered breast cancer treatment approaches, with a significant rise in neoadjuvant endocrine therapy for estrogen receptor–positive tumors, enabling immediate evidence-based treatment of women with an extremely common form of breast cancer, while delaying surgery and...

Updated Information on Sotorasib Dose-Comparison Study

Amgen has announced that it agreed with the U.S. Food and Drug Administration's proposed postmarketing requirement to conduct, as part of the ongoing development program, a multicenter randomized clinical trial to compare the safety and efficacy of sotorasib at 960 mg once daily vs a lower daily...

hematologic malignancies
immunotherapy

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on CAR T Cells for Hematologic Malignancies: Where We’re At

issues in oncology
bladder cancer
prostate cancer

YouTube Videos on Bladder Cancer: Study Focuses on Quality of Content

Social media platforms are valuable tools for educating patients about serious health topics, but they can also spread false and biased information with potentially harmful results, according to recent research published by Stacy Loeb, MD, MSc, and colleagues in European Urology. Researchers...

issues in oncology
head and neck cancer

New Research Finds Few Young Adult Men Have Received the HPV Vaccine

Using data from the 2010–2018 National Health Interview Surveys, Chen et al found that just 16% of men who were 18 to 21 years old had received at least one dose of the human papillomavirus (HPV) vaccine at any age. In comparison, 42% of women in the same age bracket had gotten at least one shot of ...

breast cancer
immunotherapy

FDA ODAC Votes in Favor of Maintaining Accelerated Approval of Atezolizumab/Nab-paclitaxel for PD-L1–Positive, Metastatic Triple-Negative Breast Cancer

Roche announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted seven to two in favor of maintaining accelerated approval of atezolizumab in combination with chemotherapy (nanoparticle albumin-bound paclitaxel, or nab-paclitaxel) for the treatment of ...

multiple myeloma

Paul G. Richardson, MD, and Peter M. Voorhees, MD, on Multiple Myeloma: Surveying the Evolving Landscape of Up-Front Drugs

lymphoma
immunotherapy

FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma

On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, ...

AACR and The Mark Foundation for Cancer Research Announce New Grants

The American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research recently announced five grants to support innovative research focused on understanding the influence of a patient’s biology on the genesis, development, treatment, and survivorship of cancer. Each...

AMA Salutes End to Ban on Transgender Americans in the Military

On January 25, 2021, Susan R. Bailey, MD, President of the American Medical Association (AMA), issued the following statement: “The AMA welcomes the President’s decision to reverse the policy that largely barred transgender people from serving in the military, because there is no medically valid...

NCI Statement on Ending Structural Racism in Biomedical Research

On March 2, 2021, the National Cancer Institute (NCI) issued the following statement: As one of the 27 institutes and centers that make up the NIH [National Institutes of Health], the National Cancer Institute stands with [NIH Director] Dr. Francis Collins and the entire NIH in supporting UNITE. “I ...

Kathy Giusti, MBA; Nancy Pelosi; and Charles L. Sawyers, MD, FAACR, to Receive AACR Distinguished Public Service Awards

The American Association for Cancer Research (AACR) will present Distinguished Public Service Awards to three individuals whose extraordinary work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, advocacy,...

IMF Launches Initiative to Improve Outcomes in Multiple Myeloma Among Black Americans

The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. The IMF is working with Atrium Health Levine Cancer Institute’s Disparities &...

Narjust Duma, MD, Appointed to Dual Role at Dana-Farber Cancer Institute/Harvard Medical School

Narjust Duma, MD, was recently named Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine at Dana-Farber Cancer Institute/Harvard Medical School. In her role at the Cancer Care Equity Program, Dr. Duma will develop strategies to diminish health-care disparities...

Brendon Stiles, MD, Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein

Leading cardiothoracic surgeon and researcher Brendon Stiles, MD, has been appointed Chief of the Division of Thoracic Surgery & Surgical Oncology in the Department of Cardiothoracic and Vascular Surgery at Montefiore Health System and Albert Einstein College of Medicine. Dr. Stiles will also...

CancerCare® Appoints Mark D. Peters II, PharmD, as Vice President for New Business Development and Outreach

CancerCare, the leading national nonprofit organization providing free support services to anyone affected by cancer, recently welcomed Mark D. Peters II, PharmD, to its team as Vice President for New Business Development and Outreach. Dr. Peters, who has more than 30 years of clinical and...

Neeraj Agarwal, MD, Named Senior Director of Clinical Research Innovation by Huntsman Cancer Institute

Huntsman Cancer Institute (HCI) at the University of Utah (U of U) announced the appointment of Neeraj Agarwal, MD, physician-scientist at HCI and Professor of Internal Medicine at the U of U, as Senior Director of Clinical Research Innovation. In this role, Dr. Agarwal will oversee critical...

gynecologic cancers

Can Brachytherapy for Cervical Cancer Continue After Uterine Perforation?

A study published by Small et al in the journal Brachytherapy found that the common procedure of interstitial or intracavitary radiotherapy may continue safely—potentially without delay or antibiotics—in patients with cervical cancer following uterine perforation. According to the World Health...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

FDA Pipeline: Bemarituzumab Granted Breakthrough Therapy Designation for FGFR2b-Overexpressing, HER2-Negative Gastric Cancer

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b)-overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma...

gynecologic cancers
immunotherapy

FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer

On April 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior...

health-care policy

NCCN 2021 Virtual Annual Conference

New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling human papillomavirus (HPV)-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021...

colorectal cancer
genomics/genetics

Study Explores Rates of Germline Mutations in Patients With Colorectal Cancer

In a recent study published by Uson Junior et al in Clinical Gastroenterology and Hepatology, researchers found one in six patients with colorectal cancer had an inherited cancer-related genetic mutation, which may be linked to a predisposition to the disease. In addition, the researchers...

immunotherapy

Immune Checkpoint Inhibitors and Cutaneous Toxicity: Population-Level Analysis

Immune checkpoint inhibitors have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a...

leukemia

Acute Myeloid Leukemia World Awareness Day 2021: April 21

After a great response to Acute Myeloid Leukemia World Awareness Day (AML WAD) in 2020, Know AML looks forward to commemorating AML WAD in 2021. AML WAD will take place on April 21, 2021, with the aim to facilitate and improve knowledge of AML worldwide through collaborative participation. Know AML ...

bladder cancer
gynecologic cancers
hepatobiliary cancer
solid tumors
colorectal cancer
immunotherapy

FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More

Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for urothelial cancer, cervical cancer, cholangiocarcinoma, solid tumors, and colorectal cancer. Acceptance of Two Supplemental Biologics License Applications for Enfortumab Vedotin-ejfv in...

breast cancer
survivorship

Overweight Breast Cancer Survivors May Be at Increased Risk of Developing a Secondary Malignancy

Breast cancer survivors who are overweight have a statistically significant increased risk of developing second primary cancers, according to results from a study conducted by Feigelson et al and published in the Journal of the National Cancer Institute. “These findings have important public health ...

leukemia
multiple myeloma
covid-19

Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma

Two new studies published in the journal Blood suggest that the BNT162b2 mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma. According to researchers, these studies could help inform the ideal time for vaccination of these...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma

Today, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. CheckMate 649 The efficacy of the...

Advertisement

Advertisement




Advertisement